drugset / Trial / NCT00720382

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

NCT00720382

Phase 3 Completed 703 enrolled Meda Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.

Timeline

Start
2007-03
Primary completion
2008-06
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelastine Small molecule 1644 ug Intranasal
Subject Mometasone furoate Other / unclassified 200 ug Intranasal